Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07130487 · ClinicalTrials.gov registry record · NA

Project CARE: CAncer Risk Evaluation

A NA study of Primary Care, sponsored by Anita Y. Kinney, PhD, RN.

Recruiting
Registry status
NA
Development phase
210
Enrollment target
1
Study location

NCT07130487: Recruiting NA study of Primary Care, sponsored by Anita Y. Kinney, PhD, RN.

NCT07130487 is a NA study of Primary Care that is actively recruiting participants, run by Anita Y. Kinney, PhD, RN. The registered enrollment target is 210 participants, below the 60,366-participant average among 5 other Primary Care trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07130487, a NA study of Primary Care, is actively recruiting participants, sponsored by Anita Y. Kinney, PhD, RN.

RECRUITING
Registry status
NA
Development phase
210 participants
Enrollment target
1
Study location

Study Summary

The purpose of Project CARE (cancer risk assessment and evaluation) research study is to explore the acceptance and feasibility of a study-initiated proactive outreach and digital care delivery model for conducting hereditary cancer risk assessment in primary care settings and facilitating genetic risk evaluation for patients flagged as high risk. Potential participants will be recruited from Rutgers Health primary care sites (family practice and general internal medicine). EPIC will be used to identify all potential participants and they will be invited to participate in the study. Consented participants will be provided a link via email, and or text message to engage with a Relational Agent (RA, chatbot), through the patient portal for cancer risk assessment and genetic education. Those identified as high risk will be offered genetic counseling and testing. The research questions the study aims to answer are: 1. What percent of patients who completed the RA are identified as high risk? 2. What percent of patients who engaged with the risk assessment were identified as high risk? 3. What percent of high-risk patients had genetic counseling or genetic testing within 4 months of completing the risk assessment?

Primary Outcome

The proportion of patients who successfully complete the hereditary cancer risk assessment within the genetic care delivery portal. Completion is defined as receiving a final result statement, regardless of whether all assessment questions in the risk assessment module were answered.

Conditions Studied

Interventions

  • BEHAVIORAL Relational Agent ( RA) Alex

Study Locations (1)

New Jersey

  • Rutgers, The State University of New Jersey - New Brunswick

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2025-11-19
Est. Completion 2026-11
Phase NA
Anita Y. Kinney, PhD, RN

1 total trials

What NCT07130487 shows while recruiting

NCT07130487 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 60,366-participant average among 5 other Primary Care trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Primary Care appearing as the primary indexed condition, and to 1 intervention - of which Relational Agent ( RA) Alex is the first listed.

NCT07130487 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT07130487 about?

NCT07130487 is a clinical study titled "Project CARE: CAncer Risk Evaluation". The purpose of Project CARE (cancer risk assessment and evaluation) research study is to explore the acceptance and feasibility of a study-initiated proactive outreach and digital care delivery model for conducting hereditary cancer risk assessment in primary care settings and facilitating genetic r...

What is the current status of trial NCT07130487?

This trial is currently recruiting. It is a NA study. The enrollment target is 210 participants. The study started on 2025-11-19. Estimated completion is 2026-11.

What conditions does trial NCT07130487 study?

This clinical trial studies the following conditions: Primary Care.

What interventions are being tested in trial NCT07130487?

The interventions under investigation include: Relational Agent ( RA) Alex (BEHAVIORAL).

Who is sponsoring clinical trial NCT07130487?

This trial is sponsored by Anita Y. Kinney, PhD, RN, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07130487 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Primary Care

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02665923 · 210 participants

    Gastric Emptying in Neonates and Infants After Formula Feeding

  • NCT03322891 · 210 participants · NA

    Improving Health Literacy in African-American Prostate Cancer Patients

  • NCT03544489 · 210 participants · Phase 2

    Effectiveness of Exercise After an ICD

  • NCT04408430 · 210 participants · NA

    The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07130487, the US trial registry maintained by the National Library of Medicine. NCT07130487 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.